Gina Mauro

The use of postoperative adjuvant radiation therapy led to less weight loss in patients with HPV-positive oropharynx cancer, according to Wade L. Thorstad, MD.

Results from a phase 1/2 trial show clinical activity of APG-115 in patients with p53 wild-type salivary gland cancer.

Findings highlight a need for individualized risk evaluation for venous thromboembolism and prophylaxis regimens for patients receiving surgery for different types of cancer.

Combining Orca-T with myeloablative BFT conditioning may improve outcomes for older patients with hematologic cancers, according to Caspian H. Oliai, MD.

Secondary primary lung cancer rates and cumulative incidence rates were similar in multiple subgroups of patients with stage T1aN0 non–small cell lung cancer.

As the 41st Annual Miami Breast Cancer Conference approaches, Debu Tripathy, MD, prepares to step down as cochair.

Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.

Both the FDA and European Medicines Agency applications were based on findings from the phase 3 CheckMate-77T trial in patients with resectable non–small cell lung cancer.

Results from the phase 2 KEYNOTE-B61 trial showed prolonged survival in patients with advanced non–clear cell renal cell carcinoma.

Neoadjuvant camrelizumab plus chemotherapy may hold promise as a standard of care in locally advanced esophageal squamous cell carcinoma, according to Yin Li, MD.

Investigators of a phase 1 trial identify no safety signals with Orca-Q in the haploidentical stem cell transplantation setting.

The combination of pelabresib plus ruxolitinib shows improvement in hemoglobin response in the MANIFEST-2 trial, supporting a potential shift in the future treatment of patients with JAK inhibitor–naive myelofibrosis.

No patients with myelodysplastic syndrome have any grade 3 or higher acute graft-versus-host disease following treatment with Orca-T in a phase 1b study.

Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.

Data from the phase 2 DESTINY-PanTumor02 trial support trastuzumab deruxtecan as a potential treatment for patients with gynecologic HER2-expressing tumors that have progressed on prior therapy.

Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.

Selpercatinib significantly improved efficacy in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer.

Many patients with relapsed/refractory multiple myeloma appear to remain on treatment with mezigdomide-based regimens for more than 1 year, according to Albert Oriol, PhD.

Patients with metastatic renal cell carcinoma, and those who have been pretreated with immune checkpoint inhibitors and are naive, saw a benefit with lenvatinib plus pembrolizumab.

Data from the phase 3 CONTACT-03 trial highlight the necessity of randomized, prospective assessment of re-challenge with checkpoint inhibitors in renal cell carcinoma, according to an expert from Dana-Farber Cancer Institute.

Patients with folate receptor alpha (FRα)–high, platinum-resistant ovarian cancer experienced progression-free survival benefit following treatment with mirvetuximab soravtansine-gynx.

Obecatagene autoleucel also appears to result in a high rate of minimal residual disease negativity in a population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Simple hysterectomy may become the new standard of care for patients with low-risk, early-stage cervical cancer, according to an expert from Université Laval in Quebec City, Canada.

A positive R0 resection rate helped to confirm the noninferiority of minimally invasive distal pancreatectomy compared with open distal pancreatectomy in those with resectable pancreatic cancer.

ALLO-316 has some “unique features” that may make it an “attractive” treatment option for those with kidney cancer, according to an expert from The University of Texas MD Anderson Cancer Center.

89Zr-DFO-girentuximab improves sensitivity and specificity in identifying clear cell kidney cancer compared with any metric to date, according to an expert from the University of California, Los Angeles.

Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.

Patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor experienced durable responses up to 48 weeks with momelotinib.

Blinatumomab plus consolidation chemotherapy produced a 58% reduction in the risk of death vs consolidation chemotherapy alone in patients with MRD-negative B-cell acute lymphoblastic leukemia.